Misforholdet mellem indberetningsfrekvensen for kombinationsbehandlingen sammenlignet med antallet af recepter indikerer en kraftig interaktion mellem de to lægemidler, som medfører øget risiko for rabdomyolyse.
The disproportion between the reporting rate on combination treatment compared with the proportion of prescriptions suggests a strong interaction between the two drugs leading to an increased risk of rhabdomyolysis.